Non-Small Cell Lung Cancer Pipeline Analysis Report 2025
Description
Non-small cell lung cancer (NSCLC) accounts for 85% of all lung cancer types. As per cancer.gov calculations, in 2024, around 234,580 new cases are likely to occur in the United States population. Moreover, 125,070 deaths are predicted in 2024. Hence, leading healthcare companies like AstraZeneca, Merck and Daiichi Sankyo along with research institutions are meticulously working to develop effective drugs for the treatment of the condition. This has led to a significant number of drugs currently in the development pipeline.
Report Coverage
The Non-Small Cell Lung Cancer (NSCLC) Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into non-small cell lung cancer therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for non-small cell lung cancer. The non-small cell lung cancer report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The non-small cell lung cancer pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from the condition, and alignment with non-small cell lung cancer treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to non-small cell lung cancer. Moreover, non-small cell lung cancer (NSCLC) collaborations and commercial assessments are offered, helping stakeholders to make informed decisions.
Non-Small Cell Lung Cancer (NSCLC) Drug Pipeline Outlook
Non-small cell lung cancer (NSCLC) is the most commonly occurring lung cancer type and can be further categorized into squamous cell carcinoma, large cell carcinoma, and adenocarcinoma. A variety of drugs are used in non-small cell lung cancer (NSCLC) treatment, depending on the stage of the cancer, specific genetic mutations, and the overall health of the patient. These drugs can be categorized into several main classes such as chemotherapy, targeted therapy, and immunotherapy, among others. Chemotherapy includes platinum-based drugs, and antimetabolites while targeted therapy constitutes EGFR inhibitors, ALK inhibitors and ROS1 inhibitors. PD-1 and PD-L1 inhibitors are also common drug classes within immunotherapy drugs.
Common symptoms of non-small cell lung cancer (NSCLC) include persistent cough, chest pain, shortness of breath and fatigue. Smoking is one of the leading causes of the condition. Therefore, the increasing prevalence of smoking in the global population fuels the non-small cell lung cancer (NSCLC) market growth.
The non-small cell lung cancer (NSCLC) pipeline report covers the pathophysiology and epidemiology, developing treatment, and the progress and future aspects of ongoing clinical trials in detail.
Non-Small Cell Lung Cancer (NSCLC) Cancer – Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of non-small cell lung cancer (NSCLC) drugs based on various segmentations such as:
By Phase
EMR’s non-small cell lung cancer (NSCLC) cancer therapeutic assessment report covers 50+ drug analysis based on phase.
EMR’s pipeline assessment report covers 50+ drug analysis based on the route of administration.
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes in depth analysis of each drug across these phases. According to EMR analysis, phase II trials cover a major share of the total non-small cell lung cancer (NSCLC) clinical trials conducted, with approximately 3,000 plus drugs in the pipeline.
Non-Small Cell Lung Cancer (NSCLC)– Pipeline Assessment Segmentation, By Route of Administration
The route of administration categories covered under the non-small cell lung cancer (NSCLC) pipeline landscape include oral, parenteral, and others. The report provides a comparative analysis of the route of administration for each drug in various phases of clinical trials. According to EMR analysis, the parenteral route holds a significant market share based on the route of administration.
Non-Small Cell Lung Cancer (NSCLC) Clinical Trials Assessment – Competitive Dynamics
The EMR non-small cell lung cancer (NSCLC) drug pipeline report insights cover the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in pancreatic cancer clinical trials:
This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs. It covers include product description, trial ID, study type, drug class, mode of administration, and recruitment status of non-small cell lung cancer (NSCLC) drug candidates.
Sasanlimab – Pfizer
Sasanlimab is a PD-1 antagonist monoclonal antibody, designed to be used in combination with a different targeted therapy in each set of the study. Sponsored by Pfizer, Sasanlimab is part of Landscape 1011 clinical research study for individuals with stage 3b or 4 NSCLC. Phase 1b of the sub-study will emphasize on analyzing the safety while phase 2 will focus on evaluating anti-tumor activity in combination.
HER3-DXd – Daiichi Sankyo
Designed to treat metastatic or unresectable non-small cell lung cancer (NSCLC), Daiichi Sankyo’s HER3-DXd is being evaluated for its efficacy and antitumor activity. The Open-Label phase 1 study is divided into two parts, including dose expansion and dose escalation. It will be assessed on individuals with advanced NSCLC, having KRAS-G12C mutation.
Osimertinib – AstraZeneca
This interventional study by AstraZeneca evaluates neoadjuvant osimertinib as monotherapy or in combination with chemotherapy, versus standard of care chemotherapy alone. Currently, under phase III, it is investigating the treatment in patients with resectable EGFRm non-small cell lung cancer.
Pembrolizumab (MK-3475) – Merck
As a part of KEYMAKER-U01 Substudy 1, a phase 2 umbrella study sponsored by Merck Sharp & Dohme LLC, pembrolizumab (MK-3475) PLUS chemotherapy in combination with vibostolimab (MK-7684), boserolimab (MK-5890), MK-4830, or MK-0482 is being evaluated for treating advanced non-small cell lung cancer.
Reasons To Buy This Report
The Non-Small Cell Lung Cancer (NSCLC) Drug Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for non-small cell lung cancer (NSCLC). It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into non-small cell lung cancer (NSCLC) collaborations, regulatory environments, and potential growth opportunities within the treatment landscape.
Key Questions Answered in the Non-Small Cell Lung Cancer (NSCLC) – Pipeline Assessment Report
Lung Cancer Therapeutics Market
Cancer Screening Market
Cancer Therapeutics Market
Report Coverage
The Non-Small Cell Lung Cancer (NSCLC) Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into non-small cell lung cancer therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for non-small cell lung cancer. The non-small cell lung cancer report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The non-small cell lung cancer pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from the condition, and alignment with non-small cell lung cancer treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to non-small cell lung cancer. Moreover, non-small cell lung cancer (NSCLC) collaborations and commercial assessments are offered, helping stakeholders to make informed decisions.
Non-Small Cell Lung Cancer (NSCLC) Drug Pipeline Outlook
Non-small cell lung cancer (NSCLC) is the most commonly occurring lung cancer type and can be further categorized into squamous cell carcinoma, large cell carcinoma, and adenocarcinoma. A variety of drugs are used in non-small cell lung cancer (NSCLC) treatment, depending on the stage of the cancer, specific genetic mutations, and the overall health of the patient. These drugs can be categorized into several main classes such as chemotherapy, targeted therapy, and immunotherapy, among others. Chemotherapy includes platinum-based drugs, and antimetabolites while targeted therapy constitutes EGFR inhibitors, ALK inhibitors and ROS1 inhibitors. PD-1 and PD-L1 inhibitors are also common drug classes within immunotherapy drugs.
Common symptoms of non-small cell lung cancer (NSCLC) include persistent cough, chest pain, shortness of breath and fatigue. Smoking is one of the leading causes of the condition. Therefore, the increasing prevalence of smoking in the global population fuels the non-small cell lung cancer (NSCLC) market growth.
The non-small cell lung cancer (NSCLC) pipeline report covers the pathophysiology and epidemiology, developing treatment, and the progress and future aspects of ongoing clinical trials in detail.
Non-Small Cell Lung Cancer (NSCLC) Cancer – Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of non-small cell lung cancer (NSCLC) drugs based on various segmentations such as:
By Phase
EMR’s non-small cell lung cancer (NSCLC) cancer therapeutic assessment report covers 50+ drug analysis based on phase.
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
EMR’s pipeline assessment report covers 50+ drug analysis based on the route of administration.
- Oral
- Parenteral
- Others
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes in depth analysis of each drug across these phases. According to EMR analysis, phase II trials cover a major share of the total non-small cell lung cancer (NSCLC) clinical trials conducted, with approximately 3,000 plus drugs in the pipeline.
Non-Small Cell Lung Cancer (NSCLC)– Pipeline Assessment Segmentation, By Route of Administration
The route of administration categories covered under the non-small cell lung cancer (NSCLC) pipeline landscape include oral, parenteral, and others. The report provides a comparative analysis of the route of administration for each drug in various phases of clinical trials. According to EMR analysis, the parenteral route holds a significant market share based on the route of administration.
Non-Small Cell Lung Cancer (NSCLC) Clinical Trials Assessment – Competitive Dynamics
The EMR non-small cell lung cancer (NSCLC) drug pipeline report insights cover the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in pancreatic cancer clinical trials:
- AstraZeneca
- Daiichi Sankyo Co., Ltd.
- GlaxoSmithKline
- Bayer AG
- Hoffmann-La Roche
- Novartis Pharmaceuticals
- Seagen Inc.
- Pfizer, Inc.
- Merck KGaA
- Others
This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs. It covers include product description, trial ID, study type, drug class, mode of administration, and recruitment status of non-small cell lung cancer (NSCLC) drug candidates.
Sasanlimab – Pfizer
Sasanlimab is a PD-1 antagonist monoclonal antibody, designed to be used in combination with a different targeted therapy in each set of the study. Sponsored by Pfizer, Sasanlimab is part of Landscape 1011 clinical research study for individuals with stage 3b or 4 NSCLC. Phase 1b of the sub-study will emphasize on analyzing the safety while phase 2 will focus on evaluating anti-tumor activity in combination.
HER3-DXd – Daiichi Sankyo
Designed to treat metastatic or unresectable non-small cell lung cancer (NSCLC), Daiichi Sankyo’s HER3-DXd is being evaluated for its efficacy and antitumor activity. The Open-Label phase 1 study is divided into two parts, including dose expansion and dose escalation. It will be assessed on individuals with advanced NSCLC, having KRAS-G12C mutation.
Osimertinib – AstraZeneca
This interventional study by AstraZeneca evaluates neoadjuvant osimertinib as monotherapy or in combination with chemotherapy, versus standard of care chemotherapy alone. Currently, under phase III, it is investigating the treatment in patients with resectable EGFRm non-small cell lung cancer.
Pembrolizumab (MK-3475) – Merck
As a part of KEYMAKER-U01 Substudy 1, a phase 2 umbrella study sponsored by Merck Sharp & Dohme LLC, pembrolizumab (MK-3475) PLUS chemotherapy in combination with vibostolimab (MK-7684), boserolimab (MK-5890), MK-4830, or MK-0482 is being evaluated for treating advanced non-small cell lung cancer.
Reasons To Buy This Report
The Non-Small Cell Lung Cancer (NSCLC) Drug Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for non-small cell lung cancer (NSCLC). It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into non-small cell lung cancer (NSCLC) collaborations, regulatory environments, and potential growth opportunities within the treatment landscape.
Key Questions Answered in the Non-Small Cell Lung Cancer (NSCLC) – Pipeline Assessment Report
- Which companies/institutions are leading the non-small cell lung cancer (NSCLC) drug development?
- What is the efficacy and safety profile of non-small cell lung cancer (NSCLC) pipeline drugs?
- Which company is leading the non-small cell lung cancer (NSCLC) pipeline development activities?
- What is the current non-small cell lung cancer (NSCLC) commercial assessment?
- What are the opportunities and challenges present in the non-small cell lung cancer (NSCLC) drug pipeline landscape?
- What is the efficacy and safety profile of non-small cell lung cancer (NSCLC) pipeline drugs?
- Which company is conducting major trials for non-small cell lung cancer (NSCLC) drugs?
- Which companies/institutions are involved in non-small cell lung cancer (NSCLC) collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in non-small cell lung cancer (NSCLC)?
Lung Cancer Therapeutics Market
Cancer Screening Market
Cancer Therapeutics Market
Table of Contents
200 Pages
- 1 Preface
- 1.1 Introduction
- 1.2 Objectives of the Study
- 1.3 Research Methodology and Assumptions
- 2 Executive Summary
- 3 Overview of Non-Small Cell Lung Cancer (NSCLC)
- 3.1 Signs and Symptoms
- 3.2 Causes
- 3.3 Risk Factors
- 3.4 Types of Non-Small Cell Lung Cancer (NSCLC)
- 3.5 Diagnosis
- 3.6 Treatment
- 4 Patient Profile
- 4.1 Patient Profile Overview
- 4.2 Patient Psychology and Emotional Impact Factors
- 4.3 Risk Assessment and Treatment Success Rate
- 5 Non-Small Cell Lung Cancer (NSCLC): Epidemiology Snapshot
- 5.1 Non-Small Cell Lung Cancer (NSCLC) Incidence by Key Markets
- 5.2 Non-Small Cell Lung Cancer (NSCLC)– Patients Seeking Treatment in Key Markets
- 6 Non-Small Cell Lung Cancer (NSCLC): Market Dynamics
- 6.1 Market Drivers and Constraints
- 6.2 SWOT Analysis
- 7 Non-Small Cell Lung Cancer (NSCLC): Key Facts Covered
- 7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
- 7.2 Top Countries Contributing to Clinical Trials in Europe
- 7.3 Top Countries Contributing to Clinical Trials in North America
- 7.4 Top Countries Contributing to Clinical Trials in Other Regions
- 8 Non-Small Cell Lung Cancer (NSCLC), Drug Pipeline Assessment
- 8.1 Assessment by Treatment Type
- 8.2 Assessment by Route of Administration
- 8.3 Assessment by Drug Class
- 9 EMR Drug Pipeline Comparative Analysis
- 9.1 List of Non-Small Cell Lung Cancer (NSCLC) Pipeline Drugs
- 9.1.1 By Company
- 9.1.2 By Phase
- 9.1.3 By Indication
- 9.1.4 By Trial Status
- 9.1.5 By Funder Type
- 9.2 EMR Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
- 10 Non-Small Cell Lung Cancer (NSCLC) Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
- 10.1 Comparative Analysis for Late-Stage Drugs
- 10.1.1 Study Type
- 10.1.2 Recruitment Status
- 10.1.3 Company
- 10.1.4 Funder Type
- 10.2 Product Level Analysis*
- 10.2.1 Durvalumab
- 10.2.1.1 Product Description
- 10.2.1.2 Trial ID
- 10.2.1.3 Sponsor Name
- 10.2.1.4 Study Type
- 10.2.1.5 Drug Class
- 10.2.1.6 Eligibility Criteria
- 10.2.1.7 Study Record Dates
- 10.2.1.7.1 First Submitted
- 10.2.1.7.2 First Posted
- 10.2.1.7.3 Last Update Posted
- 10.2.1.7.4 Last Verified
- 10.2.1.8 Indication
- 10.2.1.9 Study Design
- 10.2.1.10 Recruitment Status
- 10.2.1.11 Enrollment (Estimated)
- 10.2.1.12 Location Countries
- 10.2.1.13 Recent Results
- 10.2.2 Capmatinib
- 10.2.3 MEDI4736
- 10.2.4 TG4010
- 10.2.5 Other Drug
- 11 Non-Small Cell Lung Cancer (NSCLC) Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
- 11.1 Comparative Analysis for Mid-Stage Drugs
- 11.1.1 Study Type
- 11.1.2 Recruitment Status
- 11.1.3 Company
- 11.1.4 Funder Type
- 11.2 Product Level Analysis*
- 11.2.1 AZD2936
- 11.2.1.1 Product Description
- 11.2.1.2 Trial ID
- 11.2.1.3 Sponsor Name
- 11.2.1.4 Study Type
- 11.2.1.5 Drug Class
- 11.2.1.6 Eligibility Criteria
- 11.2.1.7 Study Record Dates
- 11.2.1.7.1 First Submitted
- 11.2.1.7.2 First Posted
- 11.2.1.7.3 Last Update Posted
- 11.2.1.7.4 Last Verified
- 11.2.1.8 Indication
- 11.2.1.9 Study Design
- 11.2.1.10 Recruitment Status
- 11.2.1.11 Enrollment (Estimated)
- 11.2.1.12 Location Countries
- 11.2.1.13 Recent Results
- 11.2.2 BPI-361175
- 11.2.3 ILX651
- 11.2.4 RAD001
- 11.2.5 Other Drugs
- 12 Non-Small Cell Lung Cancer (NSCLC) Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
- 12.1 Comparative Analysis for Early-Stage Drugs
- 12.1.1 Study Type
- 12.1.2 Recruitment Status
- 12.1.3 Company
- 12.1.4 Funder Type
- 12.2 Product Level Analysis*
- 12.2.1 BGB324
- 12.2.1.1 Product Description
- 12.2.1.2 Trial ID
- 12.2.1.3 Sponsor Name
- 12.2.1.4 Study Type
- 12.2.1.5 Drug Class
- 12.2.1.6 Eligibility Criteria
- 12.2.1.7 Study Record Dates
- 12.2.1.7.1 First Submitted
- 12.2.1.7.2 First Posted
- 12.2.1.7.3 Last Update Posted
- 12.2.1.7.4 Last Verified
- 12.2.1.8 Indication
- 12.2.1.9 Study Design
- 12.2.1.10 Recruitment Status
- 12.2.1.11 Enrollment (Estimated)
- 12.2.1.12 Location Countries
- 12.2.2 S095018
- 12.2.3 Anti-Trop2 CAR-NK cell
- 12.2.4 Other Drugs
- 13 Non-Small Cell Lung Cancer (NSCLC) Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
- 13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
- 13.1.1 Study Type
- 13.1.2 Recruitment Status
- 13.1.3 Company
- 13.1.4 Funder Type
- 13.2 Product Level Analysis*
- 13.2.1 Avelumab
- 13.2.1.1 Product Description
- 13.2.1.2 Trial ID
- 13.2.1.3 Sponsor Name
- 13.2.1.4 Study Type
- 13.2.1.5 Drug Class
- 13.2.1.6 Eligibility Criteria
- 13.2.1.7 Study Record Dates
- 13.2.1.7.1 First Submitted
- 13.2.1.7.2 First Posted
- 13.2.1.7.3 Last Update Posted
- 13.2.1.7.4 Last Verified
- 13.2.1.8 Indication
- 13.2.1.9 Study Design
- 13.2.1.10 Recruitment Status
- 13.2.1.11 Enrollment (Estimated)
- 13.2.1.12 Location Countries
- 13.2.2 Pembrolizumab
- 13.2.3 99mTc-NM-01
- 13.2.4 MPDL3280A
- 13.2.5 Other Drugs
- 14 Non-Small Cell Lung Cancer (NSCLC), Key Drug Pipeline Companies
- 14.1 AstraZeneca PLC
- 14.1.1 Company Snapshot
- 14.1.2 Pipeline Product Portfolio
- 14.1.3 Financial Analysis
- 14.1.4 Recent News and Developments
- 14.2 Novartis AG
- 14.2.1 Company Snapshot
- 14.2.2 Pipeline Product Portfolio
- 14.2.3 Financial Analysis
- 14.2.4 Recent News and Developments
- 14.3 Cipla BioTec Pvt. Ltd.
- 14.3.1 Company Snapshot
- 14.3.2 Pipeline Product Portfolio
- 14.3.3 Financial Analysis
- 14.3.4 Recent News and Developments
- 14.4 Bristol-Myers Squibb Company
- 14.4.1 Company Snapshot
- 14.4.2 Pipeline Product Portfolio
- 14.4.3 Financial Analysis
- 14.4.4 Recent News and Developments
- 14.5 GSK Plc.
- 14.5.1 Company Snapshot
- 14.5.2 Pipeline Product Portfolio
- 14.5.3 Financial Analysis
- 14.5.4 Recent News and Developments
- 14.6 Pfizer & Co., Inc.
- 14.6.1 Company Snapshot
- 14.6.2 Pipeline Product Portfolio
- 14.6.3 Financial Analysis
- 14.6.4 Recent News and Developments
- 14.7 NovoCure GmbH
- 14.7.1 Company Snapshot
- 14.7.2 Pipeline Product Portfolio
- 14.7.3 Financial Analysis
- 14.7.4 Recent News and Developments
- 15 Regulatory Framework for Drug Approval, By Region
- 16 Terminated or Suspended Pipeline Product
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
